The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management

TY - JOUR

T1 - The SOX17 phenotype in pulmonary arterial hypertension

T2 - lessons for pathobiology and clinical management

AU - Aman, Jurjan

AU - Morrell, Nicholas W.

AU - Rhodes, Christopher J.

AU - Wilkins, Martin R.

AU - Bogaard, Harm Jan

N1 - Funding Information: Support statement: J. Aman received a fellowship from the Dutch Research Council (NWO VENI: #09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10). Funding Information: Conflict of interest: J. Aman reports grants from NWO VENI (#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen ( J&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose. Funding Information: J. Aman reports grants from NWO VENI (#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen (J&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose.J. Aman received a fellowship from the Dutch Research Council (NWO VENI: #09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10).

PY - 2022/12/1

Y1 - 2022/12/1

UR - http://www.scopus.com/inward/record.url?scp=85144464003&partnerID=8YFLogxK

U2 - https://doi.org/10.1183/13993003.01438-2022

DO - https://doi.org/10.1183/13993003.01438-2022

M3 - Editorial

C2 - 37651375

SN - 0903-1936

VL - 60

JO - European respiratory journal

JF - European respiratory journal

IS - 6

M1 - 2201438

ER -